- Multidisciplinary Care
- Medical Oncology
- Metastatic Colorectal Cancer (mCRC)
- KRAS Mutation
- Gastrointestinal Oncology (GI Oncology)
- Next-Generation Sequencing (NGS)
- Immune Checkpoint Inhibitors
- Circulating Tumor DNA (ctDNA)
Which molecular alterations in colorectal cancer now change treatment and how quickly do you need the results to make the right call? On this episode of BackTable Tumor Board, Dr. Jun Gong interviews Dr. Ibrahim Sahin and Dr. Sandra Algaze about the latest advances in molecular-driven therapy across adjuvant and metastatic settings. They cover aspirin in PI3K-altered disease, the shift toward early next-generation sequencing, and the operational realities of systematic profiling at diagnosis.
Timestamps
Resources
- ALASCCA: Low-Dose Aspirin for PI3K-Altered Localized Colorectal Cancer (NEJM)
- BREAKWATER: Encorafenib, Cetuximab, and mFOLFOX6 in BRAF-Mutated Colorectal Cancer (NEJM)
- COMMIT (NRG-GI004 / SWOG-S1610): Atezolizumab Monotherapy vs mFOLFOX6/Bevacizumab/Atezolizumab in dMMR/MSI-H mCRC
- CheckMate 8HW: Nivolumab Plus Ipilimumab Versus Nivolumab in MSI-High Metastatic Colorectal Cancer (The Lancet)
- KRYSTAL-10: Adagrasib Plus Cetuximab Versus Chemotherapy in Previously Treated KRAS G12C-Mutated Colorectal Cancer
- CR-SEQUENCE: Anti-EGFR Versus Anti-VEGF Sequencing in RAS Wild-Type Left-Sided mCRC (ASCO 2026 Abstract)
More about this episode
The discussion moves from first-line BRAF and MSI-high options to anti-EGFR sequencing, ctDNA hyperselection, and the nuances of chemotherapy backbone choice. Drs. Sahin and Algaze review new trial data including BREAKWATER, KEYNOTE-177, CheckMate 8HW, KRYSTAL-10, and CR-SEQUENCE, highlight the promise and pitfalls of targeted strategies, and close with a look at emerging therapies and the multidisciplinary teamwork needed to match biology to treatment.